Fred Hutchinson Cancer Research Center, Seattle, WA
Sunil R. Hingorani , William Proctor Harris , Tara Elisabeth Seery , Lei Zheng , Darren Sigal , Andrew Eugene Hendifar , Fadi S. Braiteh , Mark Zalupski , Ari David Baron , Nathan Bahary , Andrea Wang-Gillam , Noelle K. LoConte , Gregory M. Springett , Paul S. Ritch , Aram F. Hezel , Wen Wee Ma , Venu Gopal Bathini , Xionghua W. Wu , Ping Jiang , Andrea J. Bullock
Background: Poor outcome in pancreatic cancer (PDA) is associated partly with stromal hyaluronan (HA) accumulation, which compromises chemotherapy perfusion. PEGPH20, PEGylated recombinant human hyaluronidase, potentiates chemotherapy by depleting HA in tumors. Methods: In an ongoing, phase II, open-label, randomized study of PEGPH20+nab-paclitaxel (Nab)+Gemcitabine (Gem) (PAG) vs Nab+Gem (AG) in previously untreated stage IV PDA, pts receive PEGPH20 3 µg/kg twice weekly (C1), then weekly (C2+) with standard AG dosing. HA status was tested retrospectively. After a temporary clinical hold (Apr-Jul 2014) for an imbalance in thromboembolic (TE) events (29% PAG vs 15% AG), the protocol was amended to exclude high-TE-risk pts and add enoxaparin (LMWH) prophylaxis. Endpoints are PFS and TE events (primary); PFS and ORR by HA level and OS (secondary). Efficacy and safety data through Dec 2014 are for pts enrolled up to clinical hold (Stage 1); TE data are through Sep 2015 (Stage 2). Results: 135 pts were treated (74 PAG, 61 AG). PFS results are shown below (median follow-up 7 mo). In HA-high pts receiving PAG vs AG, ORR was 52% (1 CR) vs 24% (P=.038); ORR was 37% vs 38% in HA-low pts. OS was 12 mo vs 9 mo (HR=0.62) despite 12/23 PAG pts discontinuing PEGPH20 at clinical hold. Common ADRs (PAG vs AG) included peripheral edema (58% vs 31%), muscle spasms (55% vs 1.6%), and neutropenia (32% vs 18%). TE events were: Stage 1 42% vs 25% (no LMWH); Stage 2 (with LMWH; 40 mg/d or 40 mg/d increased to 1 mg/kg/d) 28% vs 29%; (1 mg/kg/d) 5% vs 6%; overall (40 mg/d or 1 mg/kg/d) 13% each arm (to be updated). Conclusions: Pts with HA-high tumors receiving PAG, vs AG, showed significant improvements in PFS and ORR and a trend toward improved OS. PAG was well tolerated, with TE events reduced with LMWH prophylaxis. A global phase III trial of PAG will initiate Q1 2016. Clinical Trial Information: NCT01839487. Clinical trial information: NCT01839487
Population | mPFS, mo | Hazard ratio | p value | |
---|---|---|---|---|
PAG | AG | |||
Treated | 5.7 (n=74) | 5.2 (n=61) | 0.69 | .11 |
HA-high (n=44) | 9.2 (n=23) | 4.3 (n=21) | 0.39 | .05 |
HA-low (n=62) | 5.3 (n=38) | 5.6 (n=24) | 0.89 | .74 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2016 ASCO Annual Meeting
First Author: Andrea J. Bullock
2015 ASCO Annual Meeting
First Author: Sunil R. Hingorani
2022 ASCO Annual Meeting
First Author: Ying Lin
2024 ASCO Annual Meeting
First Author: Qinglian Tang